Posts

Showing posts from May, 2022

J&J Bankruptcy

Image
Bankruptcy: The BEST Way To Address Mass-Tort Claims Against Johnson & Johnson (In re LTL)   https://tinyurl.com/bdfp2tde          Plaintiff lawyers acting for women in class actions against Johnson & Johnson (J&J) have a significant conflict of interest. The actions are based on the disputed fact that ovarian cancer may follow the use of baby powder to the perineum. J&J face an estimated 40,000 claims for compensation with the result being an unstructured bankruptcy should all the claims proceed.          In response J&J have sought chapter 11-bankruptcy protection in New Jersey, the state friendliest to big business. This attempt by J&J to isolate the damage from the litigation has been portrayed as a cynical attempt to deny sick women of their rights. The new entity; Long Term Liability LLC (LTL) has been granted protection by the bankruptcy court and the reasons are...

Cost-benefit surgery

Image
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer https://tinyurl.com/ytnpprur            Surgery is always an end result of a cost-benefit decision. Will the patient be better or worse after the procedure? This retrospective study looks at the effect on survival for 549 women with ovarian cancer after major postoperative complications.          Recently surgery for ovarian cancer is becoming more aggressive with extended complete resection frequently involving peritoneum and bowel. This debulking surgery may be performed immediately on presentation (PDS), or delayed for either 3 cycles of chemo (IDS), or 6 cycles of chemo (DDS). Patients who have (PDS) are twice as likely to have postoperative complications than those who have DDS.          Postoperative complications...

Is traceback worthwhile?

Image
Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake https://tinyurl.com/2ywc9r95            Well-meaning actions may sometimes prove to be pointless. One such seems to be traceback for ovarian cancer patients. Traceback, a term first described in 2017 by the National Cancer Institute refers to the attempt to contact survivors and the families of ovarian cancer patients with the intent of performing genetic screening.          This study looked at 598 instances where traceback was attempted for women who had ovarian cancer during the period 2006 -16.  Of these women 163 were thought to be survivors and for the rest an attempt to contact family was done.          Results from this group showed only 14 (3%) made appointments for genetic screening. Less than 25% of contacts to family were successfu...

More BRCA

Image
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants https://tinyurl.com/4jjhnfj8            Discovery of the genetic basis for the hereditary breast and ovarian cancer syndrome has led to great advances in treatment options together with possible risk reduction intervention. Mutation of the BRCA1/2 gene causes defective DNA repair, which increases the risk of these two cancers.          Now with the availability of genetic profiling for many cancer patients it is possible to determine the extent of the BRCA1/2 mutation for patients who have other cancers. In a retrospective review of more than 63000 cancer patients compared to more than 37000 patients without cancer the impact of the BRCA mutation on many different cancers can be measured.          It was already known that having the BRCA mutation increases the risk of developi...